Cambridge, Massachusetts-based Biogen Inc. (BIIB) is a biotechnology company that discovers, develops, and delivers innovative therapies for serious neurological and neurodegenerative diseases. It is ...

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season.

Analysts' ratings for Biogen (NASDAQ:BIIB) over the last quarter vary from bullish to bearish, as provided by 11 analysts. The table below summarizes their recent ratings, showcasing the evolving ...

In the latest quarter, 9 analysts provided ratings for Biogen (NASDAQ:BIIB), showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by ...

During the last three months, 21 analysts shared their evaluations of Biogen (NASDAQ:BIIB), revealing diverse outlooks from bullish to bearish. In the table below, you'll find a summary of their ...

14 analysts have shared their evaluations of Biogen (NASDAQ:BIIB) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table summarizes their recent ...

One of the healthier stocks on the market Friday was veteran biotech Biogen (NASDAQ: BIIB). The company unveiled its final set of fundamentals for 2025, and it crushed analyst estimates for both ...

Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Thursday morning. Here’s what you need to know. Biogen beat analysts’ revenue expectations by 8.6% last quarter, reporting revenues ...

Key recent performance and business profile Biogen (BIIB) has moved quietly higher, with the share price showing a 0.8% decline over the last day but gains of 1.5% over the past week and 18.1% over ...

The biotech published its last set of financials for 2025. Its quarterly revenue and adjusted profitability declined, yet both still topped the consensus analyst estimates. One of the healthier stocks ...